Warning on risks: Financial contracts for difference are complex instruments and are associated with a high risk of rapid financial losses due to leverage. On 72.29% of retail investor accounts, financial losses occur when trading financial contracts for difference with this provider. You should consider whether you understand how financial contracts for difference work, and whether you can afford to take the high risk of suffering financial losses. Please read the Risk Disclosures.

Logo icon

Market analysis and news

Get an overview of current market developments with regular analysis from our analysts. We offer a detailed view of key events, economic indicators and investment opportunities. Follow the development of the markets with us and make decisions based on data and experience.

22/8/2025
Client Notice
Ozios, a registered trademark of APME FX TRADING EUROPE LTD, warns of unfair practices associated with the misuse of its brand.
More
12/8/2025
Nvidia and AMD shake up the US market with billion-dollar deals
Nvidia is an American technology company founded in 1993 that is a world leader in the manufacture of graphics processors for games, artificial intelligence (AI), data centers, and autonomous systems. It recently entered into an agreement to pay 15% of its sales revenue from Chinese AI chips to the US government in exchange for export licenses.
More
4/8/2025
One of Adobe’s Main Competitors Goes Public
The end of July brought one of the most anticipated tech IPOs of the year, as Figma went public on the New York Stock Exchange. The platform, which has redefined collaborative online design, will offer its shares within a price range of $30 to $32. [1] This is not just about another software company entering the market, but rather about Figma becoming a key player in the evolution of digital design—one that can stand shoulder to shoulder with giants like Adobe.
More
28/7/2025
AstraZeneca Seeks to Hedge Against Tariffs with an Unprecedented Investment in the US
AstraZeneca is considered one of the most innovative pharmaceutical companies today, but it is not a new drug that has recently captured attention. Rather, it's the firm’s multi-billion-dollar investment plan in the United States one of the largest commitments ever made by a European pharmaceutical company in the American market. This move is a direct response to shifting geopolitical dynamics and potential trade barriers. At the same time, it highlights how AstraZeneca continues to build a stable foundation for long-term growth across development, manufacturing, and global expansion.
More

Latest analyses